Home Blog Page 1844

Neusoft Recognized as 2025 Forbes China Go-International Series Top 30

By
Advertorial Desk
-

SHENYANG, China, Nov. 13, 2025 /PRNewswire/ — Recently, 2025 Forbes China Go-International 30&30 Series was officially released, and Neusoft Cloud Technology, a wholly-owned subsidiary of Neusoft Corporation (SSE：600718) was selected as one of the Top 30 Leading Brands for its excellent digital business & technology service capabilities and globalization practices, becoming the only technology company that provides comprehensive digital services on the list.

The Forbes China Go-International 30&30 Series Selection has been held for three consecutive years. It aims to recognize Chinese companies and representative figures excelling in global market expansion and has now become an authoritative benchmark for observing the globalization advancement of Chinese companies.

Neusoft has been actively committed to going global from the very beginning and has established a global business and service network covering multiple countries and regions, including Japan, the United States, Europe, and Southeast Asia. It serves over 20,000 clients across more than 110 countries and regions and has taken the lead or participated in the formulation of numerous national and international industry standards. Amid the rapid development of AI technology, Neusoft is expediting its dual strategy of “intelligence + globalization” to empower enterprises with a mature approach to enter the global market.

Neusoft Cloud Technology, as Neusoft’s wholly-owned subsidiary, specialized in providing digital business & technology services for global clients. Relying on Neusoft’s overall extensive global presence and exceptional software technology expertise, Neusoft Cloud Technology stands out with its core competencies in three areas: AI-driven digital experience, digital interaction, and digital infrastructure, which empowers enterprises to build global business competitiveness. Currently, Neusoft Cloud Technology has deployed a digital service and delivery network in more than 20 countries and regions worldwide, with exceptional response capabilities to serve global clients. It adopts a “China + International” dual-track model to achieve highly efficient global resource allocation and precise and locally-attuned market insights, thus forming an industry-leading intelligent service system.

Looking ahead, Neusoft will continue to empower its clients with data and AI, supporting them in achieving a full-chain overseas business expansion and integration into the global market. Meanwhile, Neusoft will continue to leverage the technologies, resources and experience accumulated in the global market to collaborate with clients, pursuing an upgrade from overseas business expansion to joint and deeper value creation, building a global value co-creation network to create more value and achieve mutual benefit and win-win growth.

For more information about Neusoft, please visit www.neusoft.com.

 

Bora 3Q25 Delivers Renewed Profitability as Efficiency and Scale Improves

By
Advertorial Desk
-

Strategic realignment powering Bora’s dual-engine businesses model


HONG KONG SAR – Media OutReach Newswire – 13 November 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for third quarter of 2025.

Quarterly Business and Financial Highlights

  • Company reported quarterly basic EPS of NT$5.09, with a loss per share of NT$1.49 from discontinued operations. Operating income reached NT$1,063 million and net income for continued operations came in at NT$822 million, resulting in quarterly EBITDA of NT$1,283 million, well on track to reclaim 2023 core P&L indicators.
  • By the end of 3Q25, Bora’s operational integration and strategic streamlining efforts have been fully executed, meeting all targeted objectives. This milestone has led to a record-high CDMO business profitability, clear evidence that Bora’s dual-engine model is now entering its next phase of balanced but scalable growth.
  • Fueled by expanded capacity and the addition of new dosage forms, Bora’s CDMO business grew 56.5% year-to-date through 3Q25, reaching over NT$7.3 billion and returning to a sequential growth trajectory.
  • Pharma sales revenues fluctuated as legacy inventory phased out, and new products are still awaiting approvals. Generics portfolio competitiveness remains a key focus area in the near term. Led by Vigafyde, Bora’s rare disease portfolio continued to gain impressive market share with the vigabatrin franchise across three dosage forms continues. The Company targets to file its next specialty pharma product by year end to accelerate the rare neurology disease business. The Company also targets to market branded Deflazacort tablets by 2025 year end as a new driver for the business.
  • The Company expects NTD to remain in the range of NTD 30-31 per USD for its operational planning.
  • Share capital increased 19.99% during the quarter from stock dividend distribution, employee stock option exercise and convertible bond conversions.
  • The Board approved Level-1 ADR issuance with each ADR share corresponding to 1/5 common share and total ADR issuance <10% of outstanding shares to enhanced market trust and investor service.


Mr. Bobby Sheng, Chairman of Bora Group, stated, “Bora executed a record level of post-merger CAPEX investment in 2025 and we are progressing in line with our strategic plan. We have expanded our Maryland aseptic fill/finish capacity by approximately 10% while solid and liquid dosage capacity in Minneapolis and Mississauga grew around 3%. The investments allowed Bora to increase our operational efficiency and increase revenue per headcount in the CDMO business by ~30% during the quarter compared to beginning of the year.

The CDMO backlog rose to US$296 million, driven by 27 new contracts and over 20 new molecules year-to-date, providing solid visibility into 2026 with 72% commercialized projects. Bora continues to leverage a unified CDMO network to enhance cost competitiveness for our very own Upsher-Smith generics portfolio, while paving the way for selective in-house manufacturing of specialty assets in the U.S.

As we look ahead, Bora is entering a phase of disciplined expansion and broader global recognition. Across our CDMO facilities in Asia and North America, we continue to actively navigate tariff and geopolitical challenges and turn them into new opportunities, strengthening supply chain resilience, and deepening collaboration with multinational partners.

On the pharma sales side, we continue to shed legacy low margin generics, increase our cashflow, and focus on our high-value generics pipeline, with certain PIV opportunities progressing to maturity in 2026. We remain dedicated on enhancing portfolio quality and increasing our Branded assets through selective specialty drugs, in order to build a more predictable and margin-accretive revenue base that mitigates product commoditization and price degredation.

In parallel, we are expanding our capital-market reach into the United States through the OTCQX Level-1 ADR program. We believe the Bora ADR will improve access and transparency for global institutional investors, while enabling overseas employees to participate in Bora’s growth. With no dilution and increasing visibility, we are laying the foundation for a stronger and more global 2026, defined by scaled growth, operational synergies, and increasing investor confidence.

3Q2025 Operational Achievements & Full Year Outlook

Global CDMO Operations

Global CDMO Operations (excluding intercompany orders from Upsher-Smith) revenues arrived at NT$1.78 billion in the third quarter and back to the sequential growth zone, representing approximately 37.13% of total revenue. A total of 418 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 33%. Year-to-date, CDMO revenues grew 18.98% over last year and reached NT$5.27 billion. Bora continues to execute on expanding this customer base to enhance business visibility and stability.

  • As the Company ramps up its Maple Grove site, the momentum for U.S. manufacturing has been encouraging. Several clinical-stage clients are now transitioning into long-term strategic partnerships, with project scale and client size both increasing. Maple Grove is well positioned to be the Center of Excellence for scale-up and U.S. supply-chain integration for Bora.
  • Large molecule CDMO operation revenues saw nearly 50% increase over the previous quarter, driven by one new ADC client and several change orders in addition to Cipla’s own labeled product launch under the collaboration agreement. Positioned as a one-stop CDMO platform alongside Bora Pharmaceuticals, Bora Biologics is now fully accelerating its CDMO operations

Pharma Sales Operations

Pharma Sales Operations in the third quarter reached a revenue of NT$3.02 billion, down 6.4% YoY, primarily due to discontinuing several products under significant pricing pressure. Pharma Sales accounted for approximately 62.83% of total revenues.

  • Discontinued loss per share (from the closure of the Plymouth production area) reflected the clearance sale of higher-cost inventories from Upsher-Smith’s legacy generics and internal supply transfer delayed by regulatory hurdles. These inventory clearance sales are now nearing completion. The greater-than-expected pricing pressure across our low margin generics reinforces the need to accelerate Bora’s transition toward higher-value and Branded specialty pharma products.
  • The Vigabatrin franchise market share expansion continues with the “total patient” indicator seeing breakthrough in October.
  • Bora continues to focus on DEE (Developmental and Epileptic Encephalopathies), where legacy compounds fail to meet significant unmet needs. The market is poised for new NCE entrants, expanding the addressable opportunity to roughly US$10 billion over the next 3–5 years. Bora aims to capture this growth through a Ready-to-Use 505(b)(2) pipeline and branded generics.

Recent Investor Conference

Bora will host an English online earnings call at 8:00 p.m. Taiwan time on Nov. 13th, 2025, followed by an investor conference hosted by Taishin Securities at the Regent Taipei at 2:30 p.m. on Nov. 14th, 2025. Both events will cover the company’s Q3’25 financial and business results and outlook.

English Online Earnings Presentation Link: https://events.q4inc.com/attendee/477519089

Bora will participate in the JP Morgan Healthcare Conference in January in San Francisco. For 1:1 meetings with management, please contact your JP Morgan representative.

Bora 2025 Earnings Schedule
Q4 2025: Expected in the 2nd week of March 2026

Hashtag: #BoraPharmaceuticals

The issuer is solely responsible for the content of this announcement.

About Bora

Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. For more information, visit .

Disclaimer:

This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.

Global Debut of FAMSCEND: Reshaping the Landscape of Agri-food Equipment Industry

By
Advertorial Desk
-

——FAMSUN Launched Its Premium New Brand

YANGZHOU, China, Nov. 13, 2025 /PRNewswire/ — On November 12, 2025, FAMSUN Co., Ltd., a globally leading player in the agri-food equipment industry, held a global launch ceremony for its premium brand FAMSCEND in Yangzhou, where its HQs are located. The event, themed “Innovate • Ascend • Nourish”, brought together over 160 industrial leaders and partners from the high-end food and pet food sectors in the world to witness the brand’s maiden voyage. It also marked FAMSUN’s official entry into the equipment industry for pet food and human healthy food, ushering in a strategic shift from scale leadership to value guidance.

Jack CHEN, President of FAMSUN, stated, “FAMSCEND will specialize in the processing equipment for pet food and human healthy foods, committed to creating sustainable value for global clients through four core capabilities – innovation, systematization, digitalization, and symbiosis.” Jason FAN, Vice President of FAMSUN, added, “The new brand will empower the global clients with more stable, efficient, and intelligent solutions.”

During the launch ceremony, seminars on cutting-edge technologies for the industry were also held, focusing on green manufacturing and intelligent trends. FAMSCEND’s comprehensive solutions and symbiotic concepts were highly recognized by its global clients.

Scenes of FAMSCEND’s global launch ceremony
Scenes of FAMSCEND’s global launch ceremony

 

Wintermute Reaches Strategic Cooperation with Leading Digital Trading Platform to Jointly Develop New Generation Quantitative Trading System

By
Advertorial Desk
-
LONDON, UK – Media OutReach Newswire – 13 November 2025 – Wintermute Trading Ltd., a globally leading cryptocurrency market maker, announced that it has reached a strategic cooperation with a renowned digital trading platform to jointly develop a new generation quantitative trading system. The two parties plan to integrate their respective advantages in algorithmic trading, liquidity provision, and market infrastructure to promote the development of digital asset trading technology.

As the core of the cooperation, Wintermute will jointly invest technical resources with its partner to build a high-performance, high-stability institutional-grade quantitative trading system, aiming to enhance trading efficiency and market liquidity, and provide a superior trading experience for a broader range of participants.

Wintermute stated that, as a global cryptocurrency market maker and liquidity provider, the company is always committed to promoting the development of the digital asset market through technological innovation, and maintains extensive cooperation with multiple leading global exchanges to jointly enhance market efficiency and stability.

Wintermute believes that deep cooperation with industry leaders is key to driving innovation and maturity in the cryptocurrency ecosystem. The company will leverage its accumulation in quantitative models and liquidity management, combined with the partner’s platform capabilities, to jointly set new technical standards for the market.

Disclaimer:
The content of this press release is published as general information and does not constitute any investment or trading advice.

Hashtag: #Wintermute

The issuer is solely responsible for the content of this announcement.

About Wintermute Trading Ltd.:

Wintermute is a leading cryptocurrency market maker and liquidity provider, focusing on DeFi and spot markets, utilizing advanced quantitative models and technical capabilities to provide liquidity support for hundreds of trading platforms and projects globally.

Yatsen Group Unveils Beauty Innovation Insight, Defining the Next Era of World-Class Beauty Science

By
Advertorial Desk
-

SHANGHAI, Nov. 13, 2025 /PRNewswire/ — Yatsen Group (NYSE: YSG), a leading multi-brand beauty company, has released Yatsen Group Beauty Innovation Insight — China’s first comprehensive report exploring innovation across beauty science, sustainability, and corporate responsibility.

The publication signals a milestone in the evolution of China’s beauty industry from brand storytelling to scientific leadership, and highlights Yatsen’s growing influence within the global research and development (R&D) community.

Yatsen Group Beauty Innovation Insight
Yatsen Group Beauty Innovation Insight

Defining Chinese Innovation from a Global Perspective

As the first white paper of its kind in China, Yatsen Group Beauty Innovation Insight centers on the theme of scientific innovation and includes six chapters spanning global R&D networks, technological breakthroughs, efficacy validation, and sustainable development.

At its launch ceremony in Shanghai’s Jing’an District, attended by government, academic, and industry leaders, Yatsen presented the white paper as both a reflection of its scientific progress and a statement of its global innovation roadmap.

David (Jinfeng) Huang, Founder, Chairman and CEO of Yatsen Group, delivers a keynote speech at the launch ceremony
David (Jinfeng) Huang, Founder, Chairman and CEO of Yatsen Group, delivers a keynote speech at the launch ceremony

“Our ambition to become a world-class technology-driven beauty pioneer is founded on years of consistent R&D investment and a commitment to scientific rigor,” said David (Jinfeng) Huang, Founder, Chairman, and CEO of Yatsen Group. “We are building a future where global research, global talent, and global markets intersect.”

Dr. Vania Leite, President of the International Federation of Societies of Cosmetic Chemists (IFSCC), contributed the report’s foreword:

“This is the first white paper from a Chinese beauty company to interpret cosmetic innovation through a global lens. Science knows no borders, and beauty knows no boundaries — this report serves as a bridge connecting China’s beauty science with the world.”

Yatsen Group Chief Scientific Officer Cheng Jing and IFSCC President Dr. Vania Leite reviewing the white paper
Yatsen Group Chief Scientific Officer Cheng Jing and IFSCC President Dr. Vania Leite reviewing the white paper

In August, Yatsen debuted the English edition of the white paper at the 35th IFSCC Congress — marking the first time Chinese cosmetic R&D achievements were presented in a comprehensive, internationally peer-reviewed format. Over the past four years, Yatsen has participated in major dermatological and cosmetic congresses, including the IFSCC, EADV, ADC, and WCD, strengthening China’s scientific voice in the global beauty dialogue.

From Lab to Market: Turning Science into Beauty

The Insight highlights how Yatsen transforms laboratory research into real consumer impact — an essential measure of innovation’s value.

Perfect Diary, Yatsen’s flagship brand, co-published the industry’s first Makeup Skinification Report with the China Association of Fragrance Flavor and Cosmetic Industries (CAFFCI) and Ruijin Hospital of Shanghai Jiao Tong University School of Medicine. The brand also launched its third-generation Biotec™ Technology, inspired by five Nobel Prize-recognized scientific discoveries that redefine how makeup enhances skin health.

In premium skincare, Galénic’s patented ActiveAnchor® technology has improved the dermal penetration of water-soluble Vitamin C, while EVE LOM has pioneered the world’s first Emotional Skincare Science framework, establishing new standards for mood-based skincare efficacy evaluation.

Yatsen’s Open Lab ecosystem connects more than 20 research collaborations across industry, academia, and medicine — including partnerships with Sun Yat-sen University, Fudan University, Ruijin Hospital, and Hôpital Saint-Louis in France. Since 2022, Yatsen has published 32 peer-reviewed papers in journals such as Science Bulletin and Nature Medicine, and has filed 252 global patents, including 78 invention applications.

“With a clear roadmap and deep interdisciplinary collaboration, we aim not only to innovate, but to lead how innovation is practiced in the beauty sector,” said Cheng Jing, Chief Scientific Officer of Yatsen Group.

Sustainable Innovation and Social Impact

Beyond R&D, Yatsen’s innovation philosophy extends to sustainability and social impact. The Group has published four consecutive ESG reports since 2021 and achieved an MSCI ESG Rating of A for two years running — the only Chinese beauty company to do so.

Yatsen Group 2024 Environmental, Social and Governance Report
Yatsen Group 2024 Environmental, Social and Governance Report

Aligned with China’s dual-carbon goals, Yatsen integrates low-carbon practices throughout its operations — from carbon audits and green sourcing to sustainable packaging. Perfect Diary’s “Slim Heel Lipstick” became one of the first beauty products in China to receive a Product Carbon Footprint Certification.

Premium brands have followed suit: EVE LOM now uses 100% FSC-certified recycled paper across all outer packaging, while Galénic has introduced refillable jar systems and removed printed inserts, cutting material usage by over 50%. The Galénic Skin Science Research Foundation further supports dermatological research globally, reinforcing Yatsen’s vision of beauty with purpose.

Galénic Couture Secret D'Excellence The Active Soft Cream
Galénic Couture Secret D’Excellence The Active Soft Cream

About Yatsen Group

Since its NYSE listing in 2020, Yatsen Group has made R&D the cornerstone of its strategy — investing more than RMB 600 million to date and maintaining R&D spending above 3% of annual revenue. The Group operates three global R&D centers in Shanghai, Guangzhou, and Toulouse (France), supported by six joint laboratories and over 20 international collaborations.

The Group’s “1-3-4-6-20 Global Research Network” includes:

  • 1 world-class biotech manufacturing facility
  • 3 proprietary R&D centers
  • 4 frontier research domains: Biotechnology, Scientific Skincare, Emotional Skincare, and Skin Data Science
  • 6 joint laboratories
  • 20+ academic and industry partnerships

Yatsen Global Innovation R&D Center
Yatsen Global Innovation R&D Center

As of mid-2025, skincare represents more than half of Yatsen’s total revenue — positioning the company among the top ten Chinese beauty enterprises by R&D investment and scientific capability.

“The future of beauty will be defined at the intersection of science, sustainability, and culture,” said David Huang. “Our mission is to help shape that future — responsibly, collaboratively, and globally.”

MP Group: Driving Health Innovation and Excellence

By
Advertorial Desk
-

BANGKOK, Nov. 13, 2025 /PRNewswire/ — MP Group (Thailand) Co., Ltd., a pioneering force in the Thai healthcare ecosystem, was proudly honored with the Corporate Excellence Award at the Asia Pacific Enterprise Awards (APEA) Thailand Chapter, organized by Enterprise Asia. This accolade celebrates the company’s remarkable journey, marked by two decades of unwavering commitment to medical innovation, holistic wellness, and empowering the community to “Live An Excellent Life.”

Founded in 2001, MP Group began as a distributor of medical diagnostic devices and has since evolved into a comprehensive healthcare solutions provider. Today, the company offers an extensive portfolio of over 1,000 SKUs, ranging from rapid diagnostic tests (RDTs) and clinical automation systems to cutting-edge technologies like next-generation sequencing (NGS) for precision medicine. By partnering with over 30 leading global manufacturers, MP Group ensures that healthcare providers nationwide have access to world-class diagnostic tools.

The company’s expansion demonstrates a strategic vision that goes beyond mere distribution. MP Group established the Health Plus Global Wellness Laboratory, a state-of-the-art service business certified with ISO 15189, solidifying its capacity for internationally recognized laboratory services. Furthermore, recognizing the importance of preventive health, MP Group has successfully ventured into the consumer health sector. Its Glass Skin skincare line is developed under the BCG (Bio-Circular-Green) Economy Model and uses scientifically-backed, eco-friendly ingredients. Expanding into nutraceuticals, home devices, and home testing solutions, MP Group brings critical screening and wellness tools closer to families, thereby playing a vital role in early detection and sustainable well-being.

MP Group’s success is underpinned by a robust corporate culture guided by its 3Ps framework: People, Process, and Profit. People are the company’s greatest strength, fostered by the PIE culture (Passion, Innovation, and Empathy) which encourages employees to be adaptable and collaborate. A process-driven mindset, focused on being “Fast and Accurate,” ensures efficiency, while Profit, driven by digital transformation and AI, enables continuous upskilling and long-term competitiveness.

Corporate responsibility is deeply embedded in MP Group’s operations. The company ensured nationwide access to diagnostic platforms and donated test kits to communities during the COVID-19 pandemic. It also supports various charitable initiatives, including donations to the Parkinson’s Patient Club and the Thai Red Cross Society.

Looking to the future, MP Group is committed to evolving into a fully digital healthcare organization, leveraging AI and automation to scale operations. By adhering to its core values and nurturing the next generation of leaders, MP Group ensures its mission—to deliver innovative, trustworthy, and accessible products that empower people to ‘Live An Excellent Life’—remains at the heart of its journey toward becoming a global healthcare leader.

About Enterprise Asia

Enterprise Asia is a non-governmental organization in pursuit of creating an Asia that is rich in entrepreneurship as an engine towards sustainable and progressive economic and social development within a world of economic equality. Its two pillars of existence are an investment in people and responsible entrepreneurship. Enterprise Asia works with governments, NGOs, and other organizations to promote competitiveness and entrepreneurial development, uplift the economic status of people across Asia, and ensure a legacy of hope, innovation, and courage for future generations. Please visit www.enterpriseasia.org for more information.

About Asia Pacific Enterprise Awards

Launched in 2007, the Asia Pacific Enterprise Awards is the region’s most prestigious award for outstanding entrepreneurship, continuous innovation, and sustainable leadership. The Award provides a platform for companies and governments to recognize entrepreneurial excellence, hence spurring greater innovation, fair business practices, and growth in entrepreneurship. As a regional award, it groups together leading entrepreneurs as a powerful voice for entrepreneurship and serves as a by-invitation-only networking powerhouse. The program has grown to encompass 16 countries/regions and markets all over Asia. For further information, please visit www.apea.asia.

Humansa and Andermatt Swiss Alps Unveil “Humansa at The Chedi Andermatt”: A World-First East-Meets-West Longevity Wellness Destination

By
Advertorial Desk
-

ANDERMATT, SWITZERLAND / HONG KONG SAR – Media OutReach Newswire – 13 November 2025 – In a landmark collaboration that redefines the future of wellness, Humansa, Asia’s leading longevity brand, partners with Andermatt Swiss Alps AG to launch “Humansa at The Chedi Andermatt”, a pioneering East-meets-West longevity destination set in the heart of the Andermatt, Switzerland. Opening later this year, this world-first concept combines AI-empowered longevity assessment, precision optimization, and refined Asian therapies within the tranquil elegance of Switzerland’s most celebrated alpine resort.

Press photo

A New Standard in Longevity Travel
“Humansa at The Chedi Andermatt ushers in a new era of longevity travel — where AI-empowered assessment and thoughtful optimization meet the world’s most elegant alpine setting,” said Don So, CEO of Humansa. “It’s a natural next step from our foundation in Humansa, uniting longevity science with Alpine hospitality. Humansa Suisse health programs emphasize what matters most — clarity through precise assessment, tailored care plans, and measurable progress delivered with discretion and care. Humansa Suisse health programs focus on what matters most — precise assessment, personalized care plans, and measurable progress delivered with discretion and care. This launch is the first chapter in what we envision as a deep and enduring partnership with Andermatt Swiss Alps, setting a new global standard together.”

Nestled amid the dramatic peaks of the Swiss Alps, this new wellness longevity hub is designed for discerning travelers seeking evidence-based vitality in an environment that blends scientific sophistication, cultural depth, and natural beauty.

Where East Meets West — The Art and Science of Longevity
At its core, Humansa at The Chedi Andermatt embodies the philosophy of East-meets-West wellbeing — a seamless union of ancient Asian healing wisdom and modern scientific innovation. Guests experience Humansa’s hallmark approach: AI-empowered diagnostics and longevity planning, paired with restorative Asian treatments and Swiss-crafted serenity.

“The Chedi Andermatt stands for Asian grace in a Swiss alpine home,” said Mr. Jörg Arnold, the General Manager at The Chedi Andermatt. “Our partnership with Humansa enriches our wellness portfolio, creating a first-in-market offering that elevates the guest experience to an unprecedented level. Together, we are shaping a new dimension of health and longevity — one that harmonizes precision and presence, performance and peace. We are thrilled to embark on this journey with Humansa and look forward to growing this partnership for years to come”

Introducing Longevity Journeys from Asia to the Alps
Building on its strong foundation in Hong Kong and across Asia, Humansa will introduce Longevity Tours to Andermatt — curated health journeys that guide clients from their personalized programs in Asia to immersive renewal in the Swiss Alps.

These experiences enable Humansa’s members to continue their data-backed wellness optimization in a pristine Alpine environment, combining advanced diagnostics with mountain air, nature therapy, and world-class hospitality.

This cross-continental model reflects Humansa’s mission to deliver seamless, measurable longevity — where science, culture, and environment converge to support lifelong vitality.

Alpine Serenity, Measurable Vitality
From ski season to summer summits, Humansa’s integrated programs deliver personalized pathways to peak performance, faster recovery, and enduring resilience. Each stay is complemented by Michelin-caliber longevity cuisine, designed to nourish cellular health and accelerate results.

Every detail — from expert-led therapies and mindfulness sessions to alpine-inspired restoration — reflects a commitment to holistic rejuvenation, where wellness is both measurable and deeply felt.

To make this pioneering approach accessible, a range of first-in-market programs will be introduced. These include an exclusive Longevity Day Pass for an immersive introduction, bespoke longevity stays for profound, personalized transformation, and curated weekend getaway programs designed for impactful rejuvenation.

A Destination for Global Wellness Seekers
For families pursuing exclusive health outcomes, travelers seeking purposeful renewal, or Humansa clients continuing their optimization journeys, Humansa at The Chedi Andermatt offers a sanctuary where science meets soul.

From Hong Kong’s dynamic energy to Switzerland’s serene altitude, this partnership symbolizes the beginning of a new global movement — one built on a long-term commitment to merge cultural intelligence, medical precision, and timeless serenity to redefine how we experience longevity.

Hashtag: #Humansa

The issuer is solely responsible for the content of this announcement.

About Humansa and Humansa Suisse

Humansa is an award-winning longevity leader, with multidisciplinary experts and global advisors to deliver programs that prioritize actionable insights. Our mission is to empower our customers to live 100+ enjoyable years. With a growing international presence, Humansa integrates advanced diagnostics, personalization, and holistic care to deliver measurable, lasting vitality.

Through Humansa Suisse AG, a Swiss-incorporated subsidiary of Humansa, we are bringing Humansa’s science-based longevity model to Europe — integrating advanced diagnostics, preventive medicine, and personalized interventions within a network of leading Swiss medical and hospitality partners. Humansa Suisse serves as the European hub of Humansa, pioneering East-meets-West approach. Together, we are redefining longevity — from extending lifespan to enriching healthspan.

About Andermatt Swiss Alps

Andermatt Swiss Alps is a company that develops and manages tourism and real estate projects in the Swiss Alps, focusing on the Andermatt and Sedrun regions. The company’s projects include the large, interconnected Andermatt+Sedrun+Disentis ski area, a luxury hotel (The Chedi Andermatt), a range of year-round activities, and modern real estate developments.

About The Chedi Andermatt

Under Andermatt Swiss Alps, The Chedi Andermatt is a five-star alpine resort known for its signature East-meets-West design, Michelin-starred dining, and world-class spa experiences. Set in the heart of the Andermatt Swiss Alps, it represents the pinnacle of refined luxury and restorative hospitality.

BGEANX Officially Obtains U.S. MSB License, Entering a New Phase of Compliant Operations

By
Advertorial Desk
-
COLORADO, US – Media OutReach Newswire – 13 November 2025 – BGEANX Exchange has recently been awarded the MSB (Money Services Business) license by the Financial Crimes Enforcement Network (FinCEN) of the U.S. Department of the Treasury, marking a significant advancement in the platform compliance operations and providing strong support for its international market expansion and global user trust.

As an integral part of the U.S. financial regulatory system, the MSB license targets financial institutions that offer currency exchange, payment processing, and digital asset transactions, requiring licensed entities to strictly adhere to KYC (Know Your Customer), AML (Anti-Money Laundering), and CFT (Countering the Financing of Terrorism) regulations. BGEANX rigorously follows these regulatory requirements to ensure fund security, transparency, and the legality of all transactions, meeting international regulatory standards.

Obtaining the MSB license means that BGEANX can offer compliant trading services to U.S. users, laying a solid foundation for entering more regulated markets in the future. The platform has established a comprehensive compliance framework and collaborates with financial security agencies and independent audit teams to create a robust fund supervision system, ensuring that all business operations comply with regulatory requirements, fully protecting legal user rights.

Currently, BGEANX is continuously upgrading in compliance operations, market expansion, and user experience. Obtaining the MSB license equips it with the capability to align with international mainstream financial platforms. Compliance is not only key to the sustainable development of exchanges but also enables BGEANX to establish close ties with more regional regulatory bodies, expanding its business footprint in the global market.

BGEANX spokesperson Seraphina stated: “Obtaining the MSB license is an important milestone on the BGEANX path to compliant operations. In the future, as the regulatory environment continues to improve, we will further optimize our compliance system, leading the crypto industry in establishing unified compliance standards, and creating a safer and fairer investment environment for global users.”

Hashtag: #BGEANX

The issuer is solely responsible for the content of this announcement.

1...1,8431,8441,845...6,491Page 1,844 of 6,491